Companies / Tvardi Therapeutics, Inc.

Tvardi Therapeutics, Inc.

Nasdaq: TVRDCIK 1346830SUGAR LAND, TX

Financials · FY2024

Revenue$7.14M
Net income$-18.21M
Total debt—
Cash$19.85M
Diluted EPS$-3.26
Shares outstanding9.4M

Ownership

9.4M shares outstanding · as of May 5, 2026
27.1%Institutions
Ownership
Institutions27.14%2,545,826
Public float72.86%6,835,518

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 9

View all →
Insider% of sharesShares
Alibhai Imran NizamudinCEOChief Executive Officer · Director
——
Conn Avi DanielChief Financial Officer
——
Hall Wallace L JrDirector
——
Kauh John Saewook M.D.Chief Medical Officer
——
O'Brien Stephen PaulPrincipal Accounting Officer
——
Shah SujalDirector
——
Shiff Susan Ph.D.Director
——
Smith CynthiaDirector
——
Wyzga Michael SDirector
——

Institutional holders 67

View all →
HolderValue% of shares
Slate Path Capital LP$3.03M7.51%
Vanguard Group Inc$1.83M4.53%
American Financial Group Inc$711.2K2.38%
Geode Capital Management, LLC$580.0K1.94%
Morgan Stanley$363.2K0.90%
Silvercrest Asset Management Group LLC$321.3K1.08%
Duncan Williams Asset Management, LLC$311.8K0.86%
Renaissance Technologies LLC$292.9K0.98%
Squarepoint Ops LLC$222.7K0.55%
Northern Trust Corp$205.9K0.51%

Activity

View all →
InsidersInstitutions
What insiders are doing in this stock (Form 4).
DateActorActionSecurityValueShares ΔPosition afterImpact
Jun 9, 2026Shiff Susan Ph.D.
Director
GrantStock Option (right to buy)—+6K
6,000
0.06% of shares
low
Jun 9, 2026Hall Wallace L Jr
Director
GrantStock Option (right to buy)—+6K
6,000
0.06% of shares
low
Jun 9, 2026Smith Cynthia
Director
GrantStock Option (right to buy)—+6K
6,000
0.06% of shares
low
Jun 9, 2026Shah Sujal
Director
GrantStock Option (right to buy)—+6K
6,000
0.06% of shares
low
Jun 9, 2026Wyzga Michael S
Director
GrantStock Option (right to buy)—+6K
6,000
0.06% of shares
low
Jan 29, 2026Conn Avi Daniel
Executive
GrantEmployee Stock Option (right to buy)—+45K
45,000
0.48% of shares
low
Jan 29, 2026O'Brien Stephen Paul
Executive
GrantEmployee Stock Option (right to buy)—+15K
15,000
0.16% of shares
low
Jan 29, 2026Alibhai Imran Nizamudin
CEO
GrantEmployee Stock Option (right to buy)—+115K
115,000
1.23% of shares
low

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
Ronald A. DePinhoPassive13G/A———

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
TVRDCommon StockEquity140755307BBG001J2QYS9